A Quarter of Doctors in Europe Can’t Define Biosimilars

19.03.2014

EuropaBio Secretary General, Nathalie Moll, speaks to Bloomberg's Makiko Kitamura about a recent survey- conducted by the Alliance of Safe Biological Medicines (ASBM)- of European doctors and their understanding, or lack their of, of biosimilar medicines.  Interestingly, the survey revealved that only one quarter of doctors contacted actually know what a biosimilar is.  Read on to find out why this is and, what industry and public bodies can do to change the situation.

Read more